Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have large...
Anna Borgenvik, Sean A. Misek, Daniel Christen et al.· bioRxiv· 1 citation
Deletion of chromosome 5q [del(5q)] is the most common cytogenetic abnormality in myelodysplastic neoplasms (MDS) and results in haploinsufficiency of multiple genes, including CSNK1A1. Recurrent CSNK1A1 mutations, predominantly affecting the E98 hotspot, occur almost exclusively in del(5q) MDS and are associated with...
Stephani Schmitz, Juliette E. Pearce, S. Martinez-Høyer et al.· Leukemia· 1 citation
Early embryogenesis relies extensively on maternally deposited products until zygotic genome activation, yet the dynamics for the synthesis of new proteins in mammalian embryos remains poorly characterized. To address this, we applied pulsed stable isotope labelling by amino acids in cell culture (pSILAC) combined with...
L. Schmidt, Maico Y. Lechner, Javier Martín-González et al.· bioRxiv· 0 citations
Protein phosphorylation orchestrates cellular signaling and controls most biological processes, with its dysregulation driving diseases, notably cancer. Comprehensive, high-throughput phosphoproteomics remains limited by detection sensitivity, data completeness and computational bottlenecks, especially in low-input set...
Claire Koenig, Hayoung Cho, K. B. Emdal et al.· Nature Structural & Molecula...· 1 citation
Applied to very small human peripheral blood mononuclear cells, this work identifies up to 4000 proteins per cell, including key markers that distinguish monocytes, T cells, and activated lymphocytes within heterogeneous populations, underscoring that single-cell proteomics can now directly elucidate clinically relevan...
I. Hendriks, Sara C. Buch-Larsen, Martin Rykær et al.· Nature Communications· 0 citations
A clinically approved PDGFRβ-targeted PET-imaging platform for longitudinal assessment of fibrotic activity in STEMI patients and preliminary observations suggest that myofibroblast activation persists for up to 2 months after STEMI in selected patients establish a translational therapeutic-diagnostic framework for ind...
Karl-Henrik Grinnemo, Ken Braesch-Andersen, Johan O. Wedin et al.· Cell Stem Cell· 1 citation
CUL3 is an injury-induced regulator of PT metabolic and stress-associated states and modulates antioxidant defense and mitochondrial metabolism in PT cells.
Turgay Saritas, Lu Chen, Sadaf Ijaz et al.· Nephrology, Dialysis and Tra...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.